Key AstraZeneca lung cancer treatment misses study goal

AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

from Reuters: Health News https://ift.tt/2zWw2Vv